1. Home
  2. Live Updates
  3. மெட்டாஸ்டேடிக் ஹார்மோன் உணர்திறன் ப்ராஸ்டேட் புற்றுநோய்

மெட்டாஸ்டேடிக் ஹார்மோன் உணர்திறன் ப்ராஸ்டேட் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மெட்டாஸ்டேடிக் ஹார்மோன் உணர்திறன் ப்ராஸ்டேட் புற்றுநோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மெட்டாஸ்டேடிக் ஹார்மோன் உணர்திறன் ப்ராஸ்டேட் புற்றுநோய் Today - Breaking & Trending Today

Astellas' and Pfizer's XTANDI® Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study

Astellas' and Pfizer's XTANDI® Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

North Carolina , United States , Andrew Armstrong , American Society Of Clinical Oncology , European Commission , Lab Abnormalities , Exchange Commission , Prostate Cancer Working Group , Astellas Pharma Inc , Pfizer Inc , European Union , European Society For Medical Oncology , Medivation Inc , Duke Cancer Institute Center , Astellas Pharma , European Society , Medical Oncology , Cancer Biology , Duke Cancer Institute , Urologic Cancers , Clinical Oncology , South America , Important Safety Information , Product Characteristics , Reversible Encephalopathy Syndrome , Heart Disease ,

Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer


Share this article
Share this article
TOKYO, May 4, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) announced today that the European Commission (EC) has approved an additional indication for the oral once-daily therapy XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). Men diagnosed with mHSPC tend to have a poor prognosis, with a median survival of approximately 3-4 years,
1 underscoring the need for new treatment options.
With this indication, enzalutamide is now the only oral treatment approved by the EC to treat three distinct types of advanced prostate cancer non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC. ....

United States , Kenji Yasukawa , Andrew Armstrong , American Society Of Clinical Oncology , European Commission , Prostate Cancer Working Group , Astellas Pharma Inc , European Medicines Agency , Prnewswire Astellas Pharma Inc , Medivation Inc , Duke Cancer Institute Center , Cancer Biology , Duke Cancer Institute , Urologic Cancers , Hormone Sensitive Prostate Cancer , Safety Information , Product Characteristics , South America , Focus Area Approach , Metastatic Hormone Sensitive Prostate Cancer , Abiraterone Acetate Combined , Xtandi Summary , Prostate Cancer , ஒன்றுபட்டது மாநிலங்களில் , ஆண்ட்ரூ ஆம்ஸ்ட்ராங் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ,

Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer

Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Kenji Yasukawa , Andrew Armstrong , American Society Of Clinical Oncology , European Commission , Prostate Cancer Working Group , Astellas Pharma Inc , European Medicines Agency , Prnewswire Astellas Pharma Inc , Medivation Inc , Duke Cancer Institute Center , Cancer Biology , Duke Cancer Institute , Urologic Cancers , Hormone Sensitive Prostate Cancer , Safety Information , Product Characteristics , South America , Focus Area Approach , Metastatic Hormone Sensitive Prostate Cancer , Abiraterone Acetate Combined , Xtandi Summary , Prostate Cancer , ஒன்றுபட்டது மாநிலங்களில் , ஆண்ட்ரூ ஆம்ஸ்ட்ராங் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ,

Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer

Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Kenji Yasukawa , Andrew Krivoshik , Astellas Press , European Medicines Authority , Oncology Development , European Commission , Drug Administration , Prostate Cancer Working Group , Astellas Pharma Inc , European Medicines Agency , Prnewswire Astellas Pharma Inc , Devices Agency , Committee For Medicinal Products Human Use , Medivation Inc , Medicinal Products , Human Use , Senior Vice President , Global Therapeutic Area Head , Hormone Sensitive Prostate Cancer , Safety Information , Product Characteristics , South America , Pharma Inc , Focus Area Approach , Astellas Collaboration ,